

# Ola Bratt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6797293/publications.pdf>

Version: 2024-02-01

75  
papers

1,745  
citations

304602

22  
h-index

289141

40  
g-index

77  
all docs

77  
docs citations

77  
times ranked

2799  
citing authors

#	ARTICLE	IF	CITATIONS
1	Absolute and Relative Risk of Cardiovascular Disease in Men With Prostate Cancer: Results From the Population-Based PCBaSe Sweden. <i>Journal of Clinical Oncology</i> , 2010, 28, 3448-3456.	0.8	173
2	Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden. <i>JAMA Oncology</i> , 2017, 3, 1393.	3.4	137
3	Magnetic Resonance and Ultrasound Image Fusion Supported Transperineal Prostate Biopsy Using the Ginsburg Protocol: Technique, Learning Points, and Biopsy Results. <i>European Urology</i> , 2016, 70, 332-340.	0.9	92
4	Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review. <i>European Urology</i> , 2018, 74, 261-280.	0.9	82
5	Five-year Nationwide Follow-up Study of Active Surveillance for Prostate Cancer. <i>European Urology</i> , 2015, 67, 233-238.	0.9	77
6	Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer. <i>European Urology</i> , 2015, 68, 53-58.	0.9	69
7	Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based Study. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw110.	3.0	69
8	The influence of prostate-specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7-10 prostate cancer in a repeat biopsy setting. <i>BJU International</i> , 2017, 119, 724-730.	1.3	66
9	Comparison of initial and tertiary centre second opinion reads of multiparametric magnetic resonance imaging of the prostate prior to repeat biopsy. <i>European Radiology</i> , 2017, 27, 2259-2266.	2.3	63
10	Optimising the number of cores for magnetic resonance imaging-guided targeted and systematic transperineal prostate biopsy. <i>BJU International</i> , 2020, 125, 260-269.	1.3	60
11	Psychiatric treatment in men with prostate cancer – Results from a Nation-wide, population-based cohort study from PCBaSe Sweden. <i>European Journal of Cancer</i> , 2011, 47, 2195-2201.	1.3	59
12	Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer. <i>European Journal of Cancer</i> , 2012, 48, 75-84.	1.3	52
13	Effects of Prostate-Specific Antigen Testing on Familial Prostate Cancer Risk Estimates. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1336-1343.	3.0	45
14	Concordance of Tumor Differentiation Among Brothers with Prostate Cancer. <i>European Urology</i> , 2012, 62, 656-661.	0.9	40
15	Prostate Cancer Death After Radiotherapy or Radical Prostatectomy: A Nationwide Population-based Observational Study. <i>European Urology</i> , 2018, 73, 502-511.	0.9	37
16	Cancer Specific Mortality in Men Diagnosed with Prostate Cancer before Age 50 Years: A Nationwide Population Based Study. <i>Journal of Urology</i> , 2017, 197, 61-66.	0.2	34
17	Accuracy of prostate biopsies for predicting Gleason score in radical prostatectomy specimens: nationwide trends 2000-2012. <i>BJU International</i> , 2017, 119, 50-56.	1.3	32
18	Defining the incremental value of 3D T2-weighted imaging in the assessment of prostate cancer extracapsular extension. <i>European Radiology</i> , 2019, 29, 5488-5497.	2.3	32

#	ARTICLE	IF	CITATIONS
19	Dashboard report on performance on select quality indicators to cancer care providers. Scandinavian Journal of Urology, 2016, 50, 21-28.	0.6	30
20	Quantification of Total and Intracellular Sodium Concentration in Primary Prostate Cancer and Adjacent Normal Prostate Tissue With Magnetic Resonance Imaging. Investigative Radiology, 2018, 53, 450-456.	3.5	28
21	Androgen deprivation therapy for prostate cancer and risk of dementia. BJU International, 2019, 124, 87-92.	1.3	26
22	The Study of Active Monitoring in Sweden (SAMS): A randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer. Scandinavian Journal of Urology, 2013, 47, 347-355.	0.6	25
23	Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: A population-based study from the National Prostate Cancer Register of Sweden. Scandinavian Journal of Urology and Nephrology, 2010, 44, 384-390.	1.4	22
24	Immediate versus delayed prostatectomy: Nationwide population-based study. Scandinavian Journal of Urology, 2016, 50, 246-254.	0.6	22
25	Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study. European Urology, 2017, 72, 125-134.	0.9	21
26	Prostate cancer diagnosis, staging, and treatment in Sweden during the first phase of the COVID-19 pandemic. Scandinavian Journal of Urology, 2021, 55, 184-191.	0.6	21
27	Defining Intermediate Risk Prostate Cancer Suitable for Active Surveillance. Journal of Urology, 2019, 201, 292-299.	0.2	21
28	Upper limit of cancer extent on biopsy defining very low-risk prostate cancer. BJU International, 2015, 116, 213-219.	1.3	20
29	Using prognosis to guide inclusion criteria, define standardised endpoints and stratify follow-up in active surveillance for prostate cancer. BJU International, 2019, 124, 758-767.	1.3	20
30	Prostate cancer in kidney transplant recipients – a nationwide register study. BJU International, 2020, 125, 679-685.	1.3	19
31	Rate and characteristics of infection after transrectal prostate biopsy: a retrospective observational study. Scandinavian Journal of Urology, 2021, 55, 317-323.	0.6	19
32	Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer. European Urology, 2017, 72, 534-541.	0.9	17
33	Satisfaction with Care Among Men with Localised Prostate Cancer: A Nationwide Population-based Study. European Urology Oncology, 2018, 1, 37-45.	2.6	16
34	A population-based study on the association between educational length, prostate-specific antigen testing and use of prostate biopsies. Scandinavian Journal of Urology, 2016, 50, 104-109.	0.6	15
35	Everyday life after a radical prostatectomy – A qualitative study of men under 65 years of age. European Journal of Oncology Nursing, 2017, 30, 107-112.	0.9	15
36	The Risk of Distant Metastases and Cancer Specific Survival in Men with Serum Prostate Specific Antigen Values above 100 ng/ml. Journal of Urology, 2015, 194, 1594-1600.	0.2	14

#	ARTICLE	IF	CITATIONS
37	The Swedish national guidelines on prostate cancer, part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease. <i>Scandinavian Journal of Urology</i> , 2022, 56, 265-273.	0.6	13
38	The Value of an Extensive Transrectal Repeat Biopsy with Anterior Sampling in Men on Active Surveillance for Low-risk Prostate Cancer: A Comparison from the Randomised Study of Active Monitoring in Sweden (SAMS). <i>European Urology</i> , 2019, 76, 461-466.	0.9	10
39	Comparative performance and external validation of the multivariable PREDICT Prostate tool for non-metastatic prostate cancer: a study in 69,206 men from Prostate Cancer data Base Sweden (PCBaSe). <i>BMC Medicine</i> , 2020, 18, 139.	2.3	10
40	The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration resistant disease. <i>Scandinavian Journal of Urology</i> , 2022, 56, 278-284.	0.6	10
41	<b>Current routines for transrectal ultrasound-guided prostate biopsy: A web-based survey by the Swedish Urology Network</b>. <i>Scandinavian Journal of Urology and Nephrology</i> , 2012, 46, 405-410.	1.4	9
42	18F-choline PET/CT for early detection of metastases in biochemical recurrence following radical prostatectomy. <i>World Journal of Urology</i> , 2015, 33, 1749-1752.	1.2	9
43	Towards “next-generation” prostate cancer screening. <i>Lancet Oncology</i> , The, 2015, 16, 1579-1580.	5.1	9
44	Nationwide, population-based study of post radical prostatectomy urinary incontinence correction surgery. <i>Journal of Surgical Oncology</i> , 2018, 117, 321-327.	0.8	8
45	Concordance of Non-“Low-Risk Disease Among Pairs of Brothers With Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1847-1852.	0.8	8
46	Determinants for choosing and adhering to active surveillance for localised prostate cancer: a nationwide population-based study. <i>BMJ Open</i> , 2019, 9, e033944.	0.8	7
47	Prediction of clinical progression after radical prostatectomy in a nationwide population-based cohort. <i>Scandinavian Journal of Urology</i> , 2016, 50, 255-259.	0.6	6
48	Changes in lifestyle among prostate cancer survivors: A nationwide population-based study. <i>Psycho-Oncology</i> , 2020, 29, 1713-1719.	1.0	6
49	Pre-treatment 18F-choline PET/CT is prognostic for biochemical recurrence, development of bone metastasis, and cancer specific mortality following radical local therapy of high-risk prostate cancer. <i>European Journal of Hybrid Imaging</i> , 2018, 2, 16.	0.6	5
50	Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 948-961.	2.0	5
51	The urologist's guide to low dose-rate interstitial brachytherapy with permanent seed implants for localized prostate cancer. <i>BJU International</i> , 2007, 99, 497-501.	1.3	4
52	Aiming for a holistic integrated service for men diagnosed with prostate cancer “ Definitions of standards and skill sets for nurses and allied healthcare professionals. <i>European Journal of Oncology Nursing</i> , 2017, 29, 31-38.	0.9	4
53	PSA decay during salvage radiotherapy for prostate cancer as a predictor of disease outcome “ 5-year follow-up of a prospective observational study. <i>Clinical and Translational Radiation Oncology</i> , 2020, 24, 23-28.	0.9	4
54	Risk of Postoperative Up Staging or Upgrading among Men with Low Risk Familial Prostate Cancer. <i>Journal of Urology</i> , 2020, 204, 79-81.	0.2	4

#	ARTICLE	IF	CITATIONS
55	Prostate biopsy quality and patient experience with the novel Forsvall biopsy needle – a randomized controlled non-inferiority trial. <i>Scandinavian Journal of Urology</i> , 2021, 55, 235-241.	0.6	3
56	The drama of prostate cancer diagnostics. <i>Lancet Oncology</i> , The, 2017, 18, e132.	5.1	2
57	Re: Peter Ström, Tobias Nordström, Henrik Grönberg, Martin Eklund. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. <i>Eur Urol</i> . In press. <a href="https://doi.org/10.1016/j.eururo.2017.12.028">https://doi.org/10.1016/j.eururo.2017.12.028</a> . <i>European Urology</i> , 2018, 74, e9.	0.9	2
58	TECLA – an innovative technical approach for prostate cancer registries. <i>Scandinavian Journal of Urology</i> , 2019, 53, 229-234.	0.6	2
59	A randomised trial comparing two protocols for transrectal prostate repeat biopsy: six lateral posterior plus six anterior cores versus a standard posterior 12-core biopsy. <i>Scandinavian Journal of Urology</i> , 2019, 53, 217-221.	0.6	2
60	The value of a first MRI and targeted biopsies after several years of active surveillance for low-risk prostate cancer – results from the SAMS trial. <i>Scandinavian Journal of Urology</i> , 2020, 54, 318-322.	0.6	2
61	Evaluation of the Forsvall biopsy needle in an <i>ex vivo</i> model of transrectal prostate biopsy – a novel needle design with the objective to reduce the risk of post-biopsy infection. <i>Scandinavian Journal of Urology</i> , 2021, 55, 227-234.	0.6	2
62	Long-term predictive value of serum PSA values obtained in clinical practice: Results from the Norwegian Prostate Cancer Consortium (NPCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5021-5021.	0.8	2
63	Is it time to abandon routine antibiotics for transperineal prostate biopsy?. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1403-1404.	4.6	2
64	Re: Risk of Malignant Melanoma in Men with Prostate Cancer. Nationwide, Population-based Cohort Study. <i>European Urology</i> , 2016, 69, 1158-1159.	0.9	1
65	Construct Validity of the Questionnaire Quality From the Patients Perspective Adapted for Surgical Prostate Cancer Patients. <i>Journal of Patient Experience</i> , 2021, 8, 237437352199884.	0.4	1
66	Has the time come for routine use of PET/CT for guiding treatment of biochemical recurrence after radical prostatectomy?. <i>Scandinavian Journal of Urology</i> , 2021, 55, 420-421.	0.6	1
67	Predictors of upgrading from low-grade cancer at prostatectomy in men with biparametric magnetic resonance imaging. <i>Central European Journal of Urology</i> , 2022, 75, 35-40.	0.2	1
68	Experience Measures after Radical Prostatectomy: A Register-Based Study Evaluating the Association between Patient-Reported Symptoms and Quality of Information. <i>Healthcare (Switzerland)</i> , 2022, 10, 519.	1.0	1
69	The Clinical Impact of Genetic Susceptibility to Prostate Cancer. <i>European Urology</i> , 2014, 66, 500-501.	0.9	0
70	Editorial Comment. <i>Journal of Urology</i> , 2016, 196, 726-726.	0.2	0
71	Reply to Glen Denner Santok and Koon Ho Rha’s Letter to the Editor re: Pär Stattin, Fredrik Sandin, Frederik Birkebæk Thomsen, et al. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecolgic, Nationwide, Population-based Study. <i>Eur Urol</i> . In press. <a href="http://dx.doi.org/10.1016/j.eururo.2016.07.023">http://dx.doi.org/10.1016/j.eururo.2016.07.023</a> . <i>European Urology</i> . 2017. 71. e115-e116.	0.9	0
72	RE: Preissner F, et al. extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. <i>The Prostate</i> . 2018;17. <i>Prostate</i> , 2018, 78, 691-691.	1.2	0

#	ARTICLE	IF	CITATIONS
73	Genetic Reasons to Walk the Extra Mile to Prevent Prostate Cancer. <i>European Urology</i> , 2019, 76, 41-42.	0.9	0
74	Modern prostate cancer diagnostics reduce overdiagnosis – will they open up for population-based screening?. <i>Scandinavian Journal of Urology</i> , 2021, 55, 491-492.	0.6	0
75	Integrating magnetic resonance imaging and prostate-specific membrane antigen positron emission tomography/computed tomography results into prostate cancer treatment decision making. <i>BJU International</i> , 2022, 129, 3-4.	1.3	0